Yanqing Xu

No ORCID on file · 7 papers in corpus · active 2021-2024

Study types

  • article 5
  • other 1
  • rct 1

Condition tags

  • endometriosis 7
  • dysmenorrhea 3
  • chronic_pelvic_pain 3
  • dyspareunia 2
rct 2024
Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2024.06.040

BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE:…

article 2023
A discrete-choice experiment study of physicians' prioritization of attributes of medical treatments for endometriosis-associated pain
Expert review of pharmacoeconomics & outcomes research ·doi:10.1080/14737167.2023.2152006

BACKGROUND: Physicians' preferences for attributes of medical treatments for endometriosis-associated pain have not previously been quantified. METHODS: US obstetrician-gynecologists completed an online discrete-choice experiment survey. I…

other 2023
The Utility and Impact of the Painful Periods Screening Tool (PPST) to Improve Healthcare Delivery for People with Symptoms of Pelvic Pain
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1007/s43032-022-01119-2

The objective of this study was to evaluate the utility and impact of the Painful Periods Screening Tool (PPST) to improve healthcare delivery for people with symptoms of pelvic pain. The design of this study was a survey study. After IRB a…

article 2022
ASSESSMENT OF PATIENT-REPORTED PAIN RELIEF IN TREATED ENDOMETRIOSIS PATIENTS: FINDINGS FROM A REAL-WORLD STUDY IN THE UNITED STATES
·doi:10.1016/j.fertnstert.2022.08.634
article 2021
A DISCRETE CHOICE EXPERIMENT STUDY OF PHYSICIANS’ PReferences FOR TREATMENTS FOR ENDOMETRIOSIS-ASSOCIATED PAIN
·doi:10.1016/j.fertnstert.2021.07.561
article 2021
REAL-WORLD EFFECTIVENESS OF ELAGOLIX IN IMPROVING ENDOMETRIOSIS QUALITY OF LIFE: 3-MONTH AND 6-MONTH INTERIM Results FROM THE ELAGOLIX LONGITUDINAL OUTCOMES (LOTUS) PROSPECTIVE COHORT STUDY
·doi:10.1016/j.fertnstert.2021.07.553
article 2021
Real-World Effectiveness of Elagolix in Reducing Endometriosis Pain: 6-Month Results from Elagolix Longitudinal Outcomes (LOTUS) Study
·doi:10.1016/j.jmig.2021.09.431